SCHEMBL15328201

SCHEMBL15328201

NC(=O)c1cccn(-c2ccc(Cl)c(Cl)c2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
F10 P00742 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK14 Q16539 1/20 0.41
MAP2K2 P36507 1/20 0.40
MAP2K1 Q02750 1/20 0.40
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
NOTUM Q6P988 1/20 0.38
PARP1 P09874 2/20 0.37
PARP2 Q9UGN5 2/20 0.37
PARP3 Q9Y6F1 2/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328325 0.84 ALDH1A1 (0.45) MAPK1ALDH1A1MAPTLMNAHPGD
SCHEMBL15328279 0.84 MAPK1 (0.55) MAPK1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL15327933 0.83 MAPK1 (0.54) MAPK1ALDH1A1MAPTLMNAHPGD
SCHEMBL1396731 0.78 MAPK1 (0.58) MAPK1ALDH1A1MAPTLMNAHPGD
SCHEMBL1161158 0.77 TYK2 (0.50) MAPK1ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL15328054 0.77 MAPK1 (0.43) MAPK1ALDH1A1MAPTLMNAHPGD
SCHEMBL29908855 0.77 PARP1 (0.44) MAPK1ALDH1A1LMNASMN1; SMN2MAPK14
Hydrochloric Acid SCHEMBL29908833 0.76 MAPK1 (0.56) MAPK1ALDH1A1MAPTLMNAHPGD
Hydrochloric Acid SCHEMBL23071632 0.76 TYK2 (0.49) MAPK1ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL15327967 0.75 KDM4E (0.63) MAPK1ALDH1A1LMNAF10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US claimed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 MAPK1 106/4885ALDH1A1 3369/4885MAPT 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.